Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers

Authors: Xiaodong Sun, Tongzhong Ju, Richard D. Cummings

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

The Tn neoantigen (GalNAcα1-O-Ser/Thr) is an O-glycan expressed in various types of human cancers. Studies in several Tn-expressing cancer cell lines and pancreatic tumors have identified loss of Cosmc expression caused by either mutations or promoter hypermethylation. In this study, we explored the mechanism(s) for Tn expression in human colorectal cancers (CRC).

Methods

Tn-expressing cell populations were isolated from CRC cell lines by Fluorescence-associated cell sorting (FACS). The expression of the Tn and sialylated Tn (STn) antigens, Cosmc, T-synthase, and mucins was characterized in paired specimens with CRC and in CRC cell lines by immunostaining, western blot, and qPCR.

Results

Using well-defined monoclonal antibodies, we confirmed prevalent Tn/STn expression in CRC samples. However, a majority of these tumors had elevated T-synthase activity and expression of both Cosmc and T-synthase proteins. Meanwhile, Tn antigen expression was not caused by mucin overproduction. In addition, we found that Tn-expressing CRC cell lines had either loss-of-function mutations in Cosmc or reversible Tn antigen expression, which was not caused by the deficiency of T-synthase activity.

Conclusions

Our results demonstrate multiple mechanisms for Tn expression in CRCs.

Available only for authorised users

Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, Cutler C, Zeng J, Wang J, Sun X, Heimburg-Molinaro J, Smith DF, Cummings RD. Proteomics Clin Appl. 2013;7:618–31. https://doi.org/10.1002/prca.201300024.PubMedPubMedCentralCrossRef

Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Adv Cancer Res. 2015;126:53–135. https://doi.org/10.1016/bs.acr.2014.11.002.CrossRefPubMedPubMedCentral

Fuster MM, Esko JD. Nat Rev Cancer. 2005;5:526–42. https://doi.org/10.1038/nrc1649.CrossRefPubMed

Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989;49:197–204.

Oshikiri T, Miyamoto M, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Takahashi T, Horita S, Kondo S. Clin Cancer Res. 2006;12:411–6. https://doi.org/10.1158/1078-0432.CCR-05-1257.CrossRefPubMed

Ju T, Otto VI, Cummings RD. Angew Chem Int Ed Engl. 2011;50:1770–91. https://doi.org/10.1002/anie.201002313.CrossRefPubMedPubMedCentral

Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer. 1997;72:119–27.

Borgert A, Heimburg-Molinaro J, Song X, Lasanajak Y, Ju T, Liu M, Thompson P, Ragupathi G, Barany G, Smith DF, Cummings RD, Live D. ACS Chem Biol. 2012;7:1031–9. https://doi.org/10.1021/cb300076s.CrossRefPubMedPubMedCentral

Wang Y, Ju T, Ding X, Xia B, Wang W, Xia L, He M, Cummings RD. Proc Natl Acad Sci U S A. 2010;107:9228–33. https://doi.org/10.1073/pnas.0914004107.CrossRefPubMedPubMedCentral

10.

Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Glycobiology. 2012;22:736–56. https://doi.org/10.1093/glycob/cwr182.CrossRefPubMed

11.

Ju T, Brewer K, D'Souza A, Cummings RD, Canfield WM. J Biol Chem. 2002;277:178–86. https://doi.org/10.1074/jbc.M109060200.CrossRefPubMed

12.

Iwai T, Inaba N, Naundorf A, Zhang Y, Gotoh M, Iwasaki H, Kudo T, Togayachi A, Ishizuka Y, Nakanishi H, Narimatsu H. J Biol Chem. 2002;277:12802–9. https://doi.org/10.1074/jbc.M112457200.CrossRefPubMed

13.

Ju T, Cummings RD. Proc Natl Acad Sci U S A. 2002;99:16613–8. https://doi.org/10.1073/pnas.262438199.CrossRefPubMedPubMedCentral

14.

Aryal RP, Ju T, Cummings RD. J Biol Chem. 2012;287:15317–29. https://doi.org/10.1074/jbc.M111.312587.CrossRefPubMedPubMedCentral

15.

Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, Vakhrushev SY, Olsen JV, Hansen L, Bennett EP, Woetmann A, Yin G, Chen L, Song H, Bak M, Hlady RA, Peters SL, Opavsky R, Thode C, Qvortrup K, Schjoldager KT, Clausen H, Hollingsworth MA, Wandall HH. Proc Natl Acad Sci U S A. 2014;111:E4066–75. https://doi.org/10.1073/pnas.1406619111.CrossRefPubMedPubMedCentral

16.

Mi R, Song L, Wang Y, Ding X, Zeng J, Lehoux S, Aryal RP, Wang J, Crew VK, van Die I, Chapman AB, Cummings RD, Ju T. J Biol Chem. 2012;287:41523–33. https://doi.org/10.1074/jbc.M112.371989.CrossRefPubMedPubMedCentral

17.

Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Cancer Res. 2008;68:1636–46. https://doi.org/10.1158/0008-5472.CAN-07-2345.CrossRefPubMed

18.

Ju T, Cummings RD. Methods Mol Biol. 2013;1022:15–28. https://doi.org/10.1007/978-1-62703-465-4_2.CrossRefPubMed

19.

Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77–99.

20.

Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci (Elite Ed). 2011;3:1443–55.

21.

Itzkowitz SH, Bloom EJ, Lau TS, Kim YS. Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps. Gut. 1992;33:518–23.

22.

Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol. 2004;12:350–5.

23.

Yu X, Du Z, Sun X, Shi C, Zhang H, Hu T. Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29. Int J Clin Exper Pathol. 2015;8:2590–602.

24.

Chen YF, Boland CR, Kraus ER, Goldstein IJ. The lectin Griffonia simplicifolia I-A4 (GS I-A4) specifically recognizes terminal alpha-linked N-acetylgalactosaminyl groups and is cytotoxic to the human colon cancer cell lines LS174t and SW1116. Int J Cancer. 1994;57:561–7.

25.

Zamri N, Masuda N, Oura F, Kabayama K, Yajima Y, Nakada H, Yamamoto K, Fujita-Yamaguchi Y. Characterization of anti-Tn-antigen MLS128 binding proteins involved in inhibiting the growth of human colorectal cancer cells. Biosci Trends. 2013;7:221–9.

26.

Vilar E, Tabernero J. Cancer Discov. 2013;3:502–11. https://doi.org/10.1158/2159-8290.CD-12-0471.CrossRefPubMedPubMedCentral

27.

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM. Cancer Res. 2014;74:3238–47. https://doi.org/10.1158/0008-5472.CAN-14-0013.CrossRefPubMed

28.

Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. Science. 2006;314:304–8. https://doi.org/10.1126/science.1129200.CrossRefPubMed

29.

Ju T, Cummings RD. Nature. 2005;437:1252. https://doi.org/10.1038/4371252a.CrossRefPubMed

30.

T.C.G.A. Network. Nature. 2012;487:330–7. https://doi.org/10.1038/nature11252.CrossRef

31.

Yoo NJ, Kim MS, Lee SH. APMIS. 2008;116:154–5. https://doi.org/10.1111/j.1600-0463.2008.00965.x.CrossRefPubMed

32.

Zeng J, Mi R, Wang Y, Li Y, Lin L, Yao B, Song L, van Die I, Chapman AB, Cummings RD, Jin P, Ju T. J Biol Chem. 2015;290:19018–33. https://doi.org/10.1074/jbc.M115.654244.CrossRefPubMedPubMedCentral

33.

Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Nat Rev Cancer. 2013;13:759–71. https://doi.org/10.1038/nrc3611.CrossRefPubMed

34.

Ni M, Lee AS. FEBS letters. 2007;581:3641–51. https://doi.org/10.1016/j.febslet.2007.04.045.CrossRefPubMedPubMedCentral

35.

Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y, Qin W. Int J Cancer. 2016;138:1824–34. https://doi.org/10.1002/ijc.29723.CrossRefPubMed

36.

Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Bachvarov D. Oncotarget. 2014;5:544–60. https://doi.org/10.18632/oncotarget.1652.PubMedPubMedCentralCrossRef

37.

Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Cancer Res. 2010;70:2759–69. https://doi.org/10.1158/0008-5472.CAN-09-3911.CrossRefPubMed

38.

Huang MJ, Hu RH, Chou CH, Hsu CL, Liu YW, Huang J, Hung JS, Lai IR, Juan HF, Yu SL, Wu YM, Huang MC. Oncotarget. 2015;6:5650–65. https://doi.org/10.18632/oncotarget.3117.PubMedPubMedCentralCrossRef

39.

Nogimori K, Hori T, Kawaguchi K, Fukui T, Mii S, Nakada H, Matsumoto Y, Yamauchi Y, Takahashi M, Furukawa K, Tetsuya O, Yokoi K, Hasegawa Y, Furukawa K. Int J Oncol. 2016;49:1369–76. https://doi.org/10.3892/ijo.2016.3638.CrossRefPubMed

40.

Stanley P. J Mol Biol. 2016;428:3166–82. https://doi.org/10.1016/j.jmb.2016.03.025.CrossRefPubMedPubMedCentral

41.

Gill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H, Bard-Chapeau EA, Bard FA. Proc Natl Acad Sci U S A. 2013;110:E3152–61. https://doi.org/10.1073/pnas.1305269110.CrossRefPubMedPubMedCentral

42.

Hassinen A, Pujol FM, Kokkonen N, Pieters C, Kihlstrom M, Korhonen K, Kellokumpu S. J Biol Chem. 2011;286:38329–40. https://doi.org/10.1074/jbc.M111.277681.CrossRefPubMedPubMedCentral

43.

Huang HH, Hassinen A, Sundaram S, Spiess AN, Kellokumpu S, Stanley P. Elife. 2015;4 https://doi.org/10.7554/eLife.08916.

44.

Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H. Proc Natl Acad Sci U S A. 2005;102:4572–7. https://doi.org/10.1073/pnas.0407983102.CrossRefPubMedPubMedCentral

45.

An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J, Xia L. J Exp Med. 2007;204:1417–29. https://doi.org/10.1084/jem.20061929.CrossRefPubMedPubMedCentral

46.

Ho CW, Lin CY, Liaw YW, Chiang HL, Chin YT, Huang RL, Lai HC, Hsu YW, Kuo PJ, Chen CE, Lin HY, Whang-Peng J, Nieh S, Fu E, Liu LF, Hwang J. Oncotarget. 2016;7:61930–44. https://doi.org/10.18632/oncotarget.11324.PubMedPubMedCentralCrossRef

47.

Peixoto A, Fernandes E, Gaiteiro C, Lima L, Azevedo R, Soares J, Cotton S, Parreira B, Neves M, Amaro T, Tavares A, Teixeira F, Palmeira C, Rangel M, Silva AM, Reis CA, Santos LL, Oliveira MJ, Ferreira JA. Oncotarget. 2016;7:63138–57. https://doi.org/10.18632/oncotarget.11257.CrossRefPubMedPubMedCentral

48.

Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, Chen J, Kobayashi M, Hosokawa M, Taniguchi A, Kojima T, Ishida N, Kawakita M, Yamamoto H, Takematsu H, Suzuki A, Kozutsumi Y, Kannagi R. Proc Natl Acad Sci U S A. 2004;101:8132–7. https://doi.org/10.1073/pnas.0402088101.CrossRefPubMedPubMedCentral

49.

Li LX, Ashikov A, Liu H, Griffith CL, Bakker H, Doering TL. Glycobiology. 2017;27:87–98. https://doi.org/10.1093/glycob/cww078.CrossRefPubMed

Title: Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers
Authors: Xiaodong Sun
Tongzhong Ju
Richard D. Cummings
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4708-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Epstein-Barr virus positive peripheral T cell lymphoma with novel variants in STAT5B of a pediatric patient: a case report

Return to work in prostate cancer survivors – findings from a prospective study on occupational reintegration following a cancer rehabilitation program

Trend analysis of the quality indicators for the Brazilian cervical cancer screening programme by region and state from 2006 to 2013

Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis

Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors

Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer